News
News
Press Release
AlliedCel, a Joint Venture Between Sysmex and JCR Pharmaceuticals, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products
- Securing the Manufacturing and Sales License for Regenerative Medicine Products Developed by JUNTEN BIO -
Sysmex Corporation
JCR Pharmaceuticals Co., Ltd.
AlliedCel Corporation
JUNTEN BIO Co., Ltd.
Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announces that AlliedCel Corporation (HQ: Kobe, Japan; President: Hiroyuki Sonoda, hereinafter “AlliedCel”), a joint venture with JCR Pharmaceuticals Co., Ltd. (HQ: Ashiya, Hyogo Prefecture; Chairman and President: Shin Ashida, hereinafter “JCR”), has entered into a license agreement with JUNTEN BIO Co., Ltd. (HQ: Chiyoda-ku, Tokyo; Representative President: Masanari Kawaminami, hereinafter “JUNTEN BIO”) to play roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101).
AlliedCel was established in October 2022 for carrying out research and development, manufacture and sales of regenerative medicine products using stem cells such as hematopoietic stem cells and other cells. In addition to the project using hematopoietic stem cell proliferation technology that AlliedCel has been promoting since its establishment, it will also move ahead on studying the possibilities of other technological developments and commercialization.
AlliedCel has recently concluded a license agreement with JUNTEN BIO to take the roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101). Inducible inhibitory T-cells (JB-101) was developed by JUNTEN BIO based on the research conducted by Juntendo University (HQ: Bunkyo-ku, Tokyo; President: Hajime Arai).
Under the supervision of Juntendo University, inducible inhibitory T-cells (JB-101) are being used in an investigator-initiated study for living donor liver transplantation patients for the indication of suppressing immune rejection and supporting withdrawal (induction of immune tolerance) from immunosuppressants that transplant patients need to take orally continuously throughout their lives when administered to them after organ transplantation. Inducible inhibitory T-cells (JB-101) was designated under Japan’s Ministry of Health, Labour and Welfare’s Sakigake Designation System in 2020 as a candidate for an innovative regenerative medicine product originating from Japan and leading the world. It is scheduled for manufacturing and sales application in fiscal year 2025. Reducing the dosage of, or withdrawing, immunosuppressants is expected to not only reduce such risks as complications or infections after an organ transplant, but also to improve the survival rate of transplanted organs.
Sysmex and JCR have combined Sysmex's expertise in quality control testing technology and its knowledge of workflows efficiency using robotics technology, including IoT with JCR's track record and know-how in developing, manufacturing, and selling regenerative medicine and other products, to establish AlliedCel for R&D and early commercialization of regenerative medicine products using stem cells and other cells. The addition of inducible inhibitory T-cells (JB-101) to AlliedCel’s existing businesses will enable us to provide appropriate treatment options to patients sooner through regenerative medicine and other products.
References
|
October 3, 2022, press release: " Sysmex and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc. -”
|
||
About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." To realize this vision, Sysmex identifies and verifies prioritized Sustainable Development Goals (SDGs) and materiality (priority issues), thereby maintaining its growth as a company that generates both social and economic value. Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit www.sysmex.co.jp/en/.
FOLLOW US 
- The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.